Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Article Dans Une Revue European Journal of Human Genetics Année : 2021

Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research

Sergio Daga
Chiara Fallerini
Margherita Baldassarri
Francesca Fava
Floriana Valentino
  • Fonction : Auteur
Gabriella Doddato
  • Fonction : Auteur
Elisa Benetti
Simone Furini
Annarita Giliberti
  • Fonction : Auteur
Rossella Tita
Sara Amitrano
  • Fonction : Auteur
Mirella Bruttini
  • Fonction : Auteur
Ilaria Meloni
Anna Maria Pinto
Francesco Raimondi
Alessandra Stella
Filippo Biscarini
Nicola Picchiotti
Pietro Pinoli
Stefano Ceri
Maurizio Sanarico
  • Fonction : Auteur
Francis Crawley
Giovanni Birolo
Alessandra Renieri
Francesca Mari
Elisa Frullanti

Résumé

Abstract Within the GEN-COVID Multicenter Study, biospecimens from more than 1000 SARS-CoV-2 positive individuals have thus far been collected in the GEN-COVID Biobank (GCB). Sample types include whole blood, plasma, serum, leukocytes, and DNA. The GCB links samples to detailed clinical data available in the GEN-COVID Patient Registry (GCPR). It includes hospitalized patients (74.25%), broken down into intubated, treated by CPAP-biPAP, treated with O 2 supplementation, and without respiratory support (9.5%, 18.4%, 31.55% and 14.8, respectively); and non-hospitalized subjects (25.75%), either pauci- or asymptomatic. More than 150 clinical patient-level data fields have been collected and binarized for further statistics according to the organs/systems primarily affected by COVID-19: heart, liver, pancreas, kidney, chemosensors, innate or adaptive immunity, and clotting system. Hierarchical clustering analysis identified five main clinical categories: (1) severe multisystemic failure with either thromboembolic or pancreatic variant; (2) cytokine storm type, either severe with liver involvement or moderate; (3) moderate heart type, either with or without liver damage; (4) moderate multisystemic involvement, either with or without liver damage; (5) mild, either with or without hyposmia. GCB and GCPR are further linked to the GCGDR, which includes data from whole-exome sequencing and high-density SNP genotyping. The data are available for sharing through the Network for Italian Genomes, found within the COVID-19 dedicated section. The study objective is to systematize this comprehensive data collection and begin identifying multi-organ involvement in COVID-19, defining genetic parameters for infection susceptibility within the population, and mapping genetically COVID-19 severity and clinical complexity among patients.

Dates et versions

hal-03402589 , version 1 (25-10-2021)

Identifiants

Citer

Sergio Daga, Chiara Fallerini, Margherita Baldassarri, Francesca Fava, Floriana Valentino, et al.. Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research. European Journal of Human Genetics, 2021, 29 (5), pp.745-759. ⟨10.1038/s41431-020-00793-7⟩. ⟨hal-03402589⟩

Collections

3IA-COTEDAZUR ANR
9 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More